Christopher Liu
Stock Analyst at LUCID CAPITAL MARKETS
(1.94)
# 3,056
Out of 4,944 analysts
6
Total ratings
33.33%
Success rate
11.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNLX Genelux | Initiates: Buy | $10 | $3.20 | +212.50% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $3.42 | +426.32% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $24.42 | +10.57% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $78.24 | -46.32% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $38.49 | -53.23% | 1 | Aug 8, 2023 |
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $3.20
Upside: +212.50%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $3.42
Upside: +426.32%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $24.42
Upside: +10.57%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $78.24
Upside: -46.32%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $38.49
Upside: -53.23%